<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="As of January 29, 2020, 7736 confirmed cases of 2019-nCoV" exact="infection" post="with 170 deaths were reported in China, and additional"/>
 <result pre="drugs available. Therefore, there is an urgent need for antiviral" exact="treatment" post="in fighting the emerging viral diseases. However, the development"/>
 <result pre="against a clinical isolate of 2019-nCoV in a cell culture" exact="infection" post="model (Wang et al.2020). The authors found that two"/>
 <result pre="and RDV (EC50â€‰=â€‰0.77Â Î¼mol/L; CC50â€‰&amp;gt;â€‰100Â Î¼mol/L; SIâ€‰&amp;gt;â€‰129.87) potently blocked virus" exact="infection" post="at low-micromolar concentration and showed high selectivity index (SI)."/>
 <result pre="compounds appear promising to be transformed into clinical drugs for" exact="treatment" post="of 2019-nCoV infections. RDV is an adenosine analogue prodrug"/>
 <result pre="virus, and respiratory syncytial virus in cell culture and mouse" exact="infection" post="models (Warren et al.2016; Sheahan et al.2017; Lo et"/>
 <result pre="identified as a potent inhibitor against 2019-nCoV in cell culture" exact="infection" post="model (Wang et al.2020). CQ, a weak base 4-aminoquinolone"/>
 <result pre="has anti-inflammatory properties and has been approved for the clinical" exact="treatment" post="of autoimmune diseases such as lupus erythematosus and rheumatoid"/>
 <result pre="al.2019). It is not surprising that CQ can suppress the" exact="infection" post="of a diverse group of viruses. CQ can efficiently"/>
 <result pre="many patients. As CQ is the first-line drug for the" exact="treatment" post="of malaria and other illnesses with a proven safe"/>
 <result pre="candidate to be applied and evaluated immediately in the clinical" exact="treatment" post="of acute 2019-nCoV infections. For benefits of 2019-nCoV patients,"/>
 <result pre="2019-nCoV epidemics. All the repurposed uses of CQ in the" exact="treatment" post="of viral diseases should comply with the regulations of"/>
 <result pre="other approved clinical drugs can be repurposed to the antiviral" exact="treatment" post="of emerging viral diseases that do have other effective"/>
 <result pre="http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and chloroquine in" exact="treatment" post="of systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395"/>
</results>
